NHS Bath and North East Somerset, Swindon and Wiltshire CCG Royal United Hospitals Bath NHS Foundation Trust Great Western Hospitals NHS Foundation Trust Salisbury NHS Foundation Trust
Betamethasone sodium phosphate 0.1% with Neomycin sulfate 0.5% eye drops
Dexamethasone (Drops)
Formulary
0.1% eye drops
Dexamethasone
(Minims®)
(Drops)
Formulary
- Bath & Swindon
Non formulary - Salisbury
0.1% preservative free eye drops in 0.5ml unit doses
Dexamethasone
(Ozurdex®)
(Intravitreal implant)
Formulary
700 micrograms intravitreal implant in applicator
For the treatment of adults with macular oedema following either branch retinal vein occlusion or central retinal vein occlusion ONLY in line with local commissioning criteria and NICE TA229.
For the treatment of patients with sight problems caused diabetic macular oedema, in line with NICE TA349.
For the treatment of patients with non-infectious uveitis, in line with NICE TA460. Only available in specialist centres (not RUH or SFT).
Dexamethasone with Neomycin and Polymyxin B sulphate (Drops and ointment)
Formulary
Dexamethasone 1 mg/gram with neomycin 3500 units/gram and polymyxin B sulfate 6000 unit per 1 gram in 3.5g eye ointment
Dexamethasone 1 mg/ml with hypromellose 5 mg/ml with neomycin (as neomycin sulfate) 3500 units/ml with polymyxin B sulfate 6000 units/ml in 5ml eye drops
Dexamethasone with Tobramycin (Drops)
Formulary
Dexamethasone 1 mg/ml with tobramycin 3 mg/ml eye drops.
Salisbury only
Non formulary in BaNES and Swindon
Fluocinolone
(Iluvien®)
(Intravitreal implant)
Formulary
For the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy. In line with NICE TA301 Nov 2013. Patients need to have gained 10 or more ETDRS letters of visual acuity between baseline and month 36 to receive a further implant at month 36 according to NICE TA301.
Note: concurrent treatment to both eyes not recommended (SPC).
A single implant releases fluocinolone for up to 36 months.
Implantation may not be repeated more frequently than every 36 months due to lack of evidence base of benefit.
GWH only - For use in herpes simplex keratitis only
These strengths are non formulary at RUH and Salisbury
....
Non Formulary Items
Prednisolone 0.5% with Neomycin 0.5%
(Predsol-N®)
(Ophthalmic drops)
Non Formulary
Discontinued
Key
Notes
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Restricted Drug
Unlicensed
Display tracking information
Link to adult BNF
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Controlled Drug
High Cost Medicine
Cancer Drugs Fund
NHS England
Homecare
CCG
High Cost Drug Approval System
Traffic Light Status Information
Status
Description
RED - Hospital only – to be prescribed by a specialist and supplied from secondary care ONLY throughout treatment.
Amber medicines are considered suitable for GP prescribing following specialist initiation or recommendation.
Shared Care - these medicines require specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red.
These medicines are appropriate for initiation in both primary and secondary care. Prescribing is appropriate within licensed or local recommendations.
Suitable for patient to be directed to buy themselves
Not currently used. We intend to include this TLS in future to highlight where a decision to use this medicine is under review.
(In use from Oct 2020) Used where a decision has been made by the BSW APC not to routinely commission this preparation for its licensed indications. Do not prescribe.
Not currently used. We intend to include this TLS in future to highlight where this medicine and indication is ONLY available through a Specialist Centre according to a NICE Highly Specialised Technology or NHSE Specialised Commission Circular / Policy.
- Bath & Swindon
Unlicensed
